Markets
The FDA bought the over-the-counter products on amazon.com in July and says Amazon's fulfillment service delivered them to consumers for third parties.
SEC Filings
The renamed company moved its Class B shares to the NYSE as SKYD and cut its $49.0 billion bridge loan to zero.
SEC Filings
BioLife has ceased to exist as a separate legal entity and asked Nasdaq to delist its stock, an 8-K shows.
Markets
BioLife is now a Repligen subsidiary after a Monday stockholder vote, and plans to deregister from the SEC.
SEC Filings
A proxy supplement adds cash, debt and discount-rate inputs behind Cantor's Supernus and Indivior valuations after two New York lawsuits.
Earnings
The company expects $65 million to $75 million in restructuring charges and reaffirmed its third-quarter and 2026 forecasts.
Markets
The deal values the home-infusion company at about $5.8 billion, with a $145,963,976 fee if Option Care Health walks away in specified cases.
SEC Filings
The Laredo bank holding company told Nasdaq it will withdraw its listing; no shareholder action is required.
SEC Filings
An 8-K says Hamill, who led about 2,500 Gilead staff, takes a Class I seat on December 1, 2026, replacing Yonatan Malca.
Earnings
North American volume carried the first quarter, while reported net income fell to $29 million from $64 million a year earlier.
SEC Filings
Kevin Lobo becomes Executive Chair on January 1, 2027, keeping his pay terms but losing eligibility for new stock awards.
SEC Filings
An 8-K shows the partners settled Regeneron's Dupixent information lawsuit and will split global profits equally on four new antibodies.